OBM Transplantation

(ISSN 2577-5820)

OBM Transplantation (ISSN 2577-5820) is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc., which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.

OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.

The journal publishes all types of articles in English. There is no restriction on the length of the papers. We encourage authors to be concise but present their results in as much detail as necessary, as reviewers are expected to emphasize scientific rigor and reproducibility.

Publication Speed (median values for papers published in 2024): Submission to First Decision: 6.7 weeks; Submission to Acceptance: 14.4 weeks; Acceptance to Publication: 4 days (1-2 days of FREE language polishing included)

Special Issue

Diagnostic Requirements Including Algorithms and Biomarkers in Liver Transplantation

Submission Deadline: March 31, 2026 (Open) Submit Now

Guest Editor

Rolf Teschke, MD, Professor (Biography)

1. Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Hanau, Germany
2. Academic Teaching Hospital of the Medical Faculty, Goethe University Frankfurt/Main, Frankfurt/Main, Germany

E-Mail

Research Interests: Hepatology; herbal hepatotoxicity; gastroenterology; alcoholic liver disease

About This Topic

Liver transplantation (LT) is an important life-saving option for patients with acute liver failure, complications of end-stage liver diseases like cirrhosis, and stage T2 hepatocellular carcinoma. Currently, the survival rates are 90% after 1 year and 70% after 5 years. Of importance are careful evaluation of candidates regarding indications and contraindications. Despite major diagnostic efforts, the causes of the liver diseases of published reports on LTs often remain unclear. To overcome these issues, it is mandatory to improve the diagnostic approaches to liver diseases. This is best done by using validated diagnostic causality algorithms combined with validated diagnostic biomarkers.

Keywords

Liver transplantation; end-stage liver diseases; cirrhosis; hepatocellular carcinoma; diagnostic causality algorithms; diagnostic biomarkers

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (transplantation@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!

Publication

Open Access Review

Acute Liver Failure Due to Assumed Drug Induced Liver Injury but Lack of Any Validated Causality Algorithm: Evidence by 36 Cohort Reports with 21,709 Cases

Received: 08 January 2025;  Published: 14 February 2025;  doi: 10.21926/obm.transplant.2501234

Abstract

Liver transplantation (LT) can be the only option for patients with acute liver failure (ALF) where medical approaches are ineffective. Causes of ALF are multiple and commonly easily detectable, but uncertainty remained on the role of drug-induced liver injury (DILI) within the published ALF cohorts. Therefore, an analysis was undertaken to [...]
Open Access Original Research

Circulating lncRNAs HOTTIP and HOTAIR as Potential Biomarkers in Crigler-Najjar Syndrome: A Preliminary Report from Shiraz Liver Transplant Research Center

Received: 05 May 2024;  Published: 04 June 2024;  doi: 10.21926/obm.transplant.2402217

Abstract

Crigler-Najjar syndrome (CNS) is a rare autosomal recessive disorder characterized by impaired bilirubin metabolism, leading to neurotoxic unconjugated bilirubin accumulation. Liver transplantation remains the only effective treatment, highlighting the need for novel diagnostic and therapeutic approaches. Long non-coding RNAs [...]
Journal Metrics
2023
CiteScore SJR SNIP
0.60.1790.17
Newsletter

TOP